Sufentanil transdermal - NAL Pharma

Drug Profile

Sufentanil transdermal - NAL Pharma

Alternative Names: NAL 1241; Sufentanyl - NAL Pharma

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator NAL Pharma
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Cancer pain

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 11 Aug 2016 Sufentanil transdermal - NAL Pharma is available for licensing as of 11 Aug 2016. http://www.nalpharma.com/licensing.php?id=4&lang=en
  • 11 Aug 2016 Clinical trials in Cancer pain (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top